CA2368812C - Combination of glucosylceramide synthesis inhibitors and glycolipid degrading enzyme in therapy - Google Patents
Combination of glucosylceramide synthesis inhibitors and glycolipid degrading enzyme in therapy Download PDFInfo
- Publication number
- CA2368812C CA2368812C CA002368812A CA2368812A CA2368812C CA 2368812 C CA2368812 C CA 2368812C CA 002368812 A CA002368812 A CA 002368812A CA 2368812 A CA2368812 A CA 2368812A CA 2368812 C CA2368812 C CA 2368812C
- Authority
- CA
- Canada
- Prior art keywords
- glycolipid
- dnj
- disease
- increasing
- agent capable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9909066.4 | 1999-04-20 | ||
GBGB9909066.4A GB9909066D0 (en) | 1999-04-20 | 1999-04-20 | Therapies |
PCT/GB2000/001560 WO2000062779A1 (en) | 1999-04-20 | 2000-04-20 | Combination of glucosylceramide synthesis inhibitors and glycolipid degrading enzyme in therapy |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2368812A1 CA2368812A1 (en) | 2000-10-26 |
CA2368812C true CA2368812C (en) | 2009-06-30 |
Family
ID=10851917
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002368812A Expired - Lifetime CA2368812C (en) | 1999-04-20 | 2000-04-20 | Combination of glucosylceramide synthesis inhibitors and glycolipid degrading enzyme in therapy |
Country Status (15)
Country | Link |
---|---|
US (2) | US20020142985A1 (ja) |
EP (2) | EP1321143A1 (ja) |
JP (1) | JP4633939B2 (ja) |
AT (1) | ATE243037T1 (ja) |
AU (1) | AU775842B2 (ja) |
BR (1) | BR0009913A (ja) |
CA (1) | CA2368812C (ja) |
DE (1) | DE60003409T2 (ja) |
ES (1) | ES2200865T3 (ja) |
GB (1) | GB9909066D0 (ja) |
IL (1) | IL140379A (ja) |
MX (1) | MXPA01010707A (ja) |
NO (1) | NO329035B1 (ja) |
WO (1) | WO2000062779A1 (ja) |
ZA (1) | ZA200108417B (ja) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6465488B1 (en) | 1997-12-11 | 2002-10-15 | Chancellor, Masters & Scholars Of The University Of Oxford | Inhibition of glycolipid biosynthesis |
EP1196190B1 (en) * | 1999-07-26 | 2003-03-19 | G.D. SEARLE & CO. | Use of long-chain n-alkyl derivatives of deoxynojirimycin and a glucocerebrosidase enzyme for the manufacture of a medicament for the treatment of glycolipid storage diseases |
GB0006539D0 (en) * | 2000-03-17 | 2000-05-10 | Oxford Glycosciences Uk Ltd | Therapies |
US20040204379A1 (en) * | 2000-06-19 | 2004-10-14 | Cheng Seng H. | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
AU2001269923A1 (en) * | 2000-06-19 | 2002-01-02 | Genzyme Corporation | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
US7138262B1 (en) | 2000-08-18 | 2006-11-21 | Shire Human Genetic Therapies, Inc. | High mannose proteins and methods of making high mannose proteins |
AU2002241853A1 (en) * | 2001-01-12 | 2002-07-24 | Oxford Glycosciences (Uk) Ltd. | Mucopolysaccharidosis therapies |
US20080185293A1 (en) * | 2002-03-27 | 2008-08-07 | Giselher Klose | Method and Apparatus for Decontamination of Fluid with One or More High Purity Electrodes |
WO2004019900A1 (en) * | 2002-08-27 | 2004-03-11 | Societe Des Produits Nestle | Preventing or treating epithelial tissue damage or hair loss |
US7429460B2 (en) | 2003-01-15 | 2008-09-30 | Yeda Research And Development Co., Ltd. | Methods of screening for inhibitors of phospholipid synthesis related to glycolipid-storage diseases |
US20050208090A1 (en) * | 2004-03-18 | 2005-09-22 | Medtronic, Inc. | Methods and systems for treatment of neurological diseases of the central nervous system |
US20090111812A1 (en) * | 2004-06-14 | 2009-04-30 | Musc Foundation For Research Development | Methods for treating inflammatory disorders |
CA2568150A1 (en) * | 2004-06-21 | 2006-01-05 | Medtronic, Inc. | Medical systems and methods for delivering compositions to cells |
US7884115B2 (en) * | 2004-09-28 | 2011-02-08 | Allergan, Inc. | Methods and compositions for the treatment of pain and other neurological conditions |
JP5457680B2 (ja) | 2006-01-24 | 2014-04-02 | アンサン バイオファーマ,インコーポレイテッド | 高分子マイクロスフェアの調製技術 |
EP1986612B1 (en) | 2006-02-07 | 2012-09-12 | Shire Human Genetic Therapies, Inc. | Stabilized composition of glucocerebrosidase |
EP3608330B1 (en) | 2008-12-16 | 2022-11-09 | Genzyme Corporation | Synthetic intermediates for preparing oligosaccharide-protein conjugates |
EP2411526A4 (en) * | 2009-03-27 | 2012-09-19 | Zacharon Pharmaceuticals Inc | MODULATORS OF GANGLIOSID BIOSYNTHESIS |
WO2011017177A1 (en) | 2009-07-28 | 2011-02-10 | Shire Human Genetic Therapies | Compositions and methods for treating gaucher disease |
WO2012001641A1 (en) | 2010-06-30 | 2012-01-05 | Actelion Pharmaceuticals Ltd | Stable pharmaceutical compositions |
KR102096752B1 (ko) | 2012-03-02 | 2020-04-02 | 샤이어 휴먼 지네틱 테라피즈 인크. | Iii형 고셔병을 치료하기 위한 조성물 및 방법 |
WO2013169936A2 (en) * | 2012-05-08 | 2013-11-14 | The Johns Hopkins University | Compositions and methods for treating cardiac hypertrophy |
EP2866792A4 (en) | 2012-06-28 | 2016-08-17 | Ansun Biopharma Inc | MICROPARTICLE FORMULATIONS FOR DELIVERY TO LOWER AND CENTRAL RESPIRATORY PATHS AND METHOD OF PREPARING THEM |
US9694056B2 (en) | 2012-07-17 | 2017-07-04 | Amicus Therapeutics, Inc. | α-galactosidase A and 1-deoxygalactonojirimycin co-formulation |
US10155027B2 (en) | 2012-07-17 | 2018-12-18 | Amicus Therapeutics, Inc. | Alpha-galactosidase A and 1-deoxygalactonojirimycin co-formulation for the treatment of fabry disease |
GB201407837D0 (en) * | 2014-05-02 | 2014-06-18 | Cambridge Entpr Ltd | Methods of cancer therapy |
US9981021B1 (en) | 2015-04-09 | 2018-05-29 | Kinetiq, Inc. | Subcutaneous therapeutic enzyme formulations, uses, and methods for generating thereof |
GB201508025D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Fabry disease gene therapy |
WO2019132004A1 (ja) * | 2017-12-28 | 2019-07-04 | 国立大学法人熊本大学 | アルツハイマー病予防剤又は治療剤、そのスクリーニング方法、及びアルツハイマー病予防用又は治療用組成物 |
WO2020046132A1 (en) | 2018-08-31 | 2020-03-05 | Leiden University | Pharmacological chaperones for enzyme treatment therapy |
NL2021840B1 (en) | 2018-10-19 | 2020-05-13 | Univ Leiden | Pharmacological Chaperones For Enzyme Treatment Therapy |
CA3164707A1 (en) | 2020-02-03 | 2021-08-12 | Ana Maria Garcia Collazo | Combination therapy for treating mps1 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US182767A (en) * | 1876-10-03 | Improvement in window-screens | ||
GB1555654A (en) | 1977-06-25 | 1979-11-14 | Exxon Research Engineering Co | Agricultural burner apparatus |
DE2853573A1 (de) | 1978-12-12 | 1980-07-03 | Bayer Ag | Herstellung von n-substituierten derivaten des l-desoxynojirimycins |
DE3038901A1 (de) | 1980-10-15 | 1982-05-06 | Bayer Ag, 5090 Leverkusen | Verfahren zur herstellung von n-substituierten derivaten des 1-desoxynojirimycins |
US5151519A (en) | 1990-05-07 | 1992-09-29 | G. D. Searle & Co. | Process for the preparation of 1,5-(alkylimino)-1,5-dideoxy-d-glucitol and derivatives thereof |
US6291657B1 (en) | 1993-05-13 | 2001-09-18 | Monsanto Company | Deoxygalactonojirimycin derivatives |
ATE322900T1 (de) * | 1996-07-15 | 2006-04-15 | Macrozyme Dnm B V | Deoxynojirimycin derivate und ihre verwendung als glukosesylceramidase-inhibitoren |
US6610703B1 (en) * | 1998-12-10 | 2003-08-26 | G.D. Searle & Co. | Method for treatment of glycolipid storage diseases |
GB9909064D0 (en) * | 1999-04-20 | 1999-06-16 | Oxford Glycosciences Uk Ltd | Therapies |
EP1196190B1 (en) * | 1999-07-26 | 2003-03-19 | G.D. SEARLE & CO. | Use of long-chain n-alkyl derivatives of deoxynojirimycin and a glucocerebrosidase enzyme for the manufacture of a medicament for the treatment of glycolipid storage diseases |
AU2001269923A1 (en) * | 2000-06-19 | 2002-01-02 | Genzyme Corporation | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
-
1999
- 1999-04-20 GB GBGB9909066.4A patent/GB9909066D0/en not_active Ceased
-
2000
- 2000-04-20 WO PCT/GB2000/001560 patent/WO2000062779A1/en active IP Right Grant
- 2000-04-20 ES ES00920920T patent/ES2200865T3/es not_active Expired - Lifetime
- 2000-04-20 IL IL140379A patent/IL140379A/en not_active IP Right Cessation
- 2000-04-20 EP EP03005215A patent/EP1321143A1/en not_active Withdrawn
- 2000-04-20 AT AT00920920T patent/ATE243037T1/de not_active IP Right Cessation
- 2000-04-20 DE DE60003409T patent/DE60003409T2/de not_active Expired - Lifetime
- 2000-04-20 JP JP2000611915A patent/JP4633939B2/ja not_active Expired - Fee Related
- 2000-04-20 BR BR0009913-9A patent/BR0009913A/pt not_active Application Discontinuation
- 2000-04-20 EP EP00920920A patent/EP1171128B1/en not_active Expired - Lifetime
- 2000-04-20 MX MXPA01010707A patent/MXPA01010707A/es active IP Right Grant
- 2000-04-20 CA CA002368812A patent/CA2368812C/en not_active Expired - Lifetime
- 2000-04-20 AU AU41332/00A patent/AU775842B2/en not_active Ceased
-
2001
- 2001-10-12 ZA ZA200108417A patent/ZA200108417B/xx unknown
- 2001-10-19 NO NO20015111A patent/NO329035B1/no not_active IP Right Cessation
- 2001-10-19 US US10/042,527 patent/US20020142985A1/en not_active Abandoned
-
2004
- 2004-01-15 US US10/758,247 patent/US7348000B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
ZA200108417B (en) | 2003-03-26 |
IL140379A (en) | 2006-09-05 |
WO2000062779A1 (en) | 2000-10-26 |
JP4633939B2 (ja) | 2011-02-16 |
ATE243037T1 (de) | 2003-07-15 |
DE60003409T2 (de) | 2004-05-19 |
EP1171128A1 (en) | 2002-01-16 |
CA2368812A1 (en) | 2000-10-26 |
NO20015111D0 (no) | 2001-10-19 |
EP1171128B1 (en) | 2003-06-18 |
US20020142985A1 (en) | 2002-10-03 |
GB9909066D0 (en) | 1999-06-16 |
MXPA01010707A (es) | 2002-08-20 |
NO329035B1 (no) | 2010-08-02 |
BR0009913A (pt) | 2002-01-08 |
US20050075305A1 (en) | 2005-04-07 |
JP2002542194A (ja) | 2002-12-10 |
NO20015111L (no) | 2001-12-12 |
EP1321143A1 (en) | 2003-06-25 |
AU4133200A (en) | 2000-11-02 |
US7348000B2 (en) | 2008-03-25 |
IL140379A0 (en) | 2002-02-10 |
DE60003409D1 (de) | 2003-07-24 |
AU775842B2 (en) | 2004-08-19 |
ES2200865T3 (es) | 2004-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2368812C (en) | Combination of glucosylceramide synthesis inhibitors and glycolipid degrading enzyme in therapy | |
Andersson et al. | N-butyldeoxygalactonojirimycin: a more selective inhibitor of glycosphingolipid biosynthesis than N-butyldeoxynojirimycin, in vitro and in vivo | |
Schoser et al. | Therapeutic approaches in glycogen storage disease type II/Pompe Disease | |
Perucca et al. | Disposition of sodium valproate in epileptic patients. | |
KR101648987B1 (ko) | 프로토파낙사디올계 진세노사이드 조성물 및 그의 용도 | |
US8252789B2 (en) | Compositions and methods for treating lysosomal disorders | |
WO2010056413A2 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED α-SYNUCLEIN FUNCTION | |
JPH01254623A (ja) | スフインゴ糖脂質代謝の阻害剤を有効成分として含有する癌治療薬 | |
PT1301201E (pt) | Tratamento da doença de armazenamento de glicogénio tipo ii | |
JP2007509925A (ja) | デオキシノジリマイシン誘導体又はその薬学的塩の使用 | |
KR20160094848A (ko) | 이미노당을 사용한 당지질 억제 | |
EP3989962A1 (en) | Combination therapy with acetyl-leucine and miglustat | |
WO2003068255A1 (en) | Compositions and methods for improving enzyme replacement therapy of lysosomal storage diseases | |
Matassini et al. | Carbohydrate‐Based Therapeutics for Lysosomal Storage Disorders | |
KR20100126326A (ko) | 알츠하이머 병 치료용 의약의 제조를 위한 s-아데노실메티오닌(sam) 및 슈퍼옥시드 디스뮤타아제(sod)의 용도 | |
Brady | Gaucher and Fabry diseases: from understanding pathophysiology to rational therapies | |
US20030069200A1 (en) | Use of glucosylceramide synthesis inhibitors in brain cancertherapy | |
AU2014265137A1 (en) | Compositions and methods for the treatment of altered alpha-synuclein function | |
Mehta et al. | Co-administration with the pharmacological chaperone AT1001 increases recombinant human [alpha]-galactosidase A tissue uptake and improves substrate reduction in Fabry mice | |
CALZETTI et al. | DISPOSITION OF SODIUM VALPROATE IN EPILEPTIC PATIENTS | |
US20130040990A1 (en) | SYNTHESIS OF DGJNAc FROM D-GLUCURONOLACTONE AND USE TO INHIBIT ALPHA-N-ACETYLGALACTOSAMINIDASES | |
WO2014102417A1 (es) | UTILIZACIÓN DE DERIVADOS BICÍCLICOS DE 1-DESOXIGALACTONOJIRIMICINA EN LA PREPARACIÓN DE UN MEDICAMENTO PARA EL TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON ß-ENZIMAS GALACTOSIDASAS LISOSÓMICAS MUTANTES HUMANAS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |
Effective date: 20200420 |